Overview

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers
Phase:
Phase 2
Details
Lead Sponsor:
Brendan Lucey
Collaborator:
Eisai Inc.
Treatments:
Lemborexant